JPWO2020014505A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020014505A5 JPWO2020014505A5 JP2021500881A JP2021500881A JPWO2020014505A5 JP WO2020014505 A5 JPWO2020014505 A5 JP WO2020014505A5 JP 2021500881 A JP2021500881 A JP 2021500881A JP 2021500881 A JP2021500881 A JP 2021500881A JP WO2020014505 A5 JPWO2020014505 A5 JP WO2020014505A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- monomer
- antigen
- polypeptide
- domain monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 207
- 102000038129 antigens Human genes 0.000 claims description 207
- 108091007172 antigens Proteins 0.000 claims description 207
- 239000000178 monomer Substances 0.000 claims description 192
- 229920001184 polypeptide Polymers 0.000 claims description 178
- 230000035772 mutation Effects 0.000 claims description 66
- 238000010276 construction Methods 0.000 claims description 25
- 102000004965 antibodies Human genes 0.000 claims description 10
- 108090001123 antibodies Proteins 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 230000035693 Fab Effects 0.000 claims 4
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 43
- 238000005755 formation reaction Methods 0.000 description 43
- 239000000833 heterodimer Substances 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 28
- 238000010586 diagram Methods 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 15
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 108010045030 monoclonal antibodies Proteins 0.000 description 9
- 102000005614 monoclonal antibodies Human genes 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 4
- 108010045555 obinutuzumab Proteins 0.000 description 4
- 210000003719 B-Lymphocytes Anatomy 0.000 description 3
- 102100015545 FCGR2A Human genes 0.000 description 3
- 102100015541 FCGR3A Human genes 0.000 description 3
- 101710044656 FCGR3A Proteins 0.000 description 3
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960003347 obinutuzumab Drugs 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 102100005826 CD19 Human genes 0.000 description 2
- 101700087100 CD19 Proteins 0.000 description 2
- 102100007290 CD274 Human genes 0.000 description 2
- 101710012053 CD274 Proteins 0.000 description 2
- 102100005310 CTLA4 Human genes 0.000 description 2
- 101700054183 CTLA4 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940054499 Gazyva Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696673P | 2018-07-11 | 2018-07-11 | |
| US62/696,673 | 2018-07-11 | ||
| PCT/US2019/041438 WO2020014505A2 (en) | 2018-07-11 | 2019-07-11 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530992A JP2021530992A (ja) | 2021-11-18 |
| JPWO2020014505A5 true JPWO2020014505A5 (pt) | 2022-07-20 |
Family
ID=69141701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500881A Withdrawn JP2021530992A (ja) | 2018-07-11 | 2019-07-11 | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210317227A1 (pt) |
| EP (1) | EP3820518A4 (pt) |
| JP (1) | JP2021530992A (pt) |
| KR (1) | KR20210043582A (pt) |
| CN (1) | CN113382749A (pt) |
| AU (1) | AU2019301684A1 (pt) |
| BR (1) | BR112021000415A2 (pt) |
| CA (1) | CA3106242A1 (pt) |
| IL (1) | IL280044A (pt) |
| MX (1) | MX2021000280A (pt) |
| WO (1) | WO2020014505A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022019131A2 (pt) * | 2020-05-21 | 2022-11-29 | Zydus Lifesciences Ltd | Variante fc e composiçâo |
| KR20230066317A (ko) * | 2020-07-10 | 2023-05-15 | 바이오몰레큘러 홀딩스 엘엘씨 | 사면체 항체 |
| CN116888149A (zh) * | 2020-12-31 | 2023-10-13 | 信达生物制药(苏州)有限公司 | 含异二聚体抗体Fc的蛋白以及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101580938B1 (ko) * | 2007-06-01 | 2015-12-30 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
| EP2748197A2 (en) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| BR112015003459A2 (pt) * | 2012-08-20 | 2017-09-26 | Gliknik Inc | moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente |
| WO2014108198A1 (en) * | 2013-01-10 | 2014-07-17 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| PL3137506T3 (pl) * | 2014-05-02 | 2024-02-26 | Momenta Pharmaceuticals, Inc. | Kompozycje i sposoby powiązane z uzyskanymi metodami inżynierii konstruktami fc |
| EP3347375B1 (en) * | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
| US20220153833A1 (en) * | 2016-03-02 | 2022-05-19 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| SG10202011624SA (en) * | 2016-05-23 | 2021-01-28 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| MX2019006141A (es) * | 2016-12-09 | 2019-08-14 | Gliknik Inc | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. |
| US20200040084A1 (en) * | 2017-01-06 | 2020-02-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
-
2019
- 2019-07-11 US US17/259,443 patent/US20210317227A1/en not_active Abandoned
- 2019-07-11 AU AU2019301684A patent/AU2019301684A1/en not_active Abandoned
- 2019-07-11 KR KR1020217004250A patent/KR20210043582A/ko not_active Application Discontinuation
- 2019-07-11 MX MX2021000280A patent/MX2021000280A/es unknown
- 2019-07-11 EP EP19833960.8A patent/EP3820518A4/en not_active Withdrawn
- 2019-07-11 CA CA3106242A patent/CA3106242A1/en active Pending
- 2019-07-11 CN CN201980059592.5A patent/CN113382749A/zh active Pending
- 2019-07-11 BR BR112021000415-7A patent/BR112021000415A2/pt not_active IP Right Cessation
- 2019-07-11 JP JP2021500881A patent/JP2021530992A/ja not_active Withdrawn
- 2019-07-11 WO PCT/US2019/041438 patent/WO2020014505A2/en unknown
-
2021
- 2021-01-10 IL IL280044A patent/IL280044A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210061925A1 (en) | Trispecific and/or trivalent binding proteins | |
| US11845795B2 (en) | NKp46 binding proteins | |
| Labrijn et al. | When binding is enough: nonactivating antibody formats | |
| US20220226469A1 (en) | Therapeutic sirp-alpha antibodies | |
| KR20200085828A (ko) | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 | |
| CN102574921B (zh) | 双特异性死亡受体激动型抗体 | |
| CN105189557A (zh) | 四价双特异性抗体 | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JPWO2019129221A5 (pt) | ||
| JP7566766B2 (ja) | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 | |
| CN104968682A (zh) | 针对CD3ε和BCMA的双特异性抗体 | |
| JP2021526820A (ja) | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 | |
| CN103249742A (zh) | 抗人肿瘤坏死因子1型受体抗体 | |
| JP2009523459A5 (pt) | ||
| US20210253736A1 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| US20230030674A1 (en) | Humanized cldn18.2 antibodies | |
| CA3139508A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| CA3205036A1 (en) | Multispecific antibodies having specificity for il-4r and il-31 | |
| JP2024511319A (ja) | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 | |
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| US20240190987A1 (en) | Engineered EpCam Binding Antibodies | |
| JPWO2020076970A5 (pt) | ||
| Strohl | Therapeutic monoclonal antibodies: past, present, and future | |
| Emery et al. | Section Review: Humanised monoclonal antibodies for therapeutic applications | |
| JPWO2020014505A5 (pt) |